Shire, Microsoft and EURORDIS-Rare Diseases Europe announced a strategic alliance to address the diagnostic challenge for patients living with a rare disease.
Scholar Rock – a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment – announced the publication of “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting,” in Scientific Reports, the peer-reviewed, open-access journal published by Nature.
